தேசிய உட்செலுத்துதல் மையம் சங்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேசிய உட்செலுத்துதல் மையம் சங்கம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேசிய உட்செலுத்துதல் மையம் சங்கம் Today - Breaking & Trending Today

Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19


Press release content from PR Newswire. The AP news staff was not involved in its creation.
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
July 20, 2021 GMT
TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron’s casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19. This marks the first time the antibody cocktail, known as REGEN-COVTM in the U.S. and Ronapreve™ in other countries, has received a full approval to treat COVID-19. Emergency or temporary pandemic use authorizations are currently in place in more than 20 countries, including in the U.S., European Union, India, Switzerland and Canada. ....

South Africa , United States , Sarah Cornhill , Georged Yancopoulos , Regeneron Velocimmune , Vesna Tosic , Prnewswire Regeneron Pharmaceuticals Inc , Human Service Office Of The , Regeneron Velocimmune Technology , Teva Pharmaceutical Industries Ltd , Japan Ministry Of Health , Department Of Health , European Union , Regeneron Pharmaceuticals Inc , Biomedical Advanced Research , Regeneron Genetics Center , Human Services , Us Department Of Health , Drug Administration , Development Authority , Exchange Commission , National Infusion Center Association , Chief Scientific Officer , Special Approval Pathway , Medical Devices , Human Service Office ,